ImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter Fiscal Year 2015 Financial Results
April 09 2015 - 8:00AM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that
develops novel anticancer therapeutics using its antibody-drug
conjugate (ADC) technology, today announced that the Company will
host a conference call at 8:00 a.m. ET on Friday, April 24, 2015,
to discuss ImmunoGen's financial results for the three-month period
ended March 31, 2015, the third quarter of its 2015 fiscal year.
Management will also provide an update on the Company and the
financial guidance.
To access the live call by phone, dial 913-312-0966; the
conference ID is 2370723. The call also may be accessed through the
Investors section of the Company's website, www.immunogen.com.
Following the live webcast, a replay of the call will be available
at the same location through May 8, 2015.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The
Company’s ADC technology uses tumor-targeting antibodies to deliver
an ImmunoGen cell-killing agent specifically to cancer cells. The
Company utilizes its ADC technology with its antibodies to create
ImmunoGen product candidates and also out-licenses limited rights
to use its technology to other companies. Roche’s Kadcyla® is the
first marketed product with ImmunoGen’s ADC technology. More
information about the Company can be found at
www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of the
Roche Group.
For Investors:ImmunoGen, Inc.Carol Hausner,
781-895-0600info@immunogen.comorFor Media:Pure Communications,
Inc.Dan Budwick, 973-271-6085
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Apr 2023 to Apr 2024